Scarica l'app Stockscreener
25.74
1.42%
0.36
Dopo l'orario di chiusura:
25.70
-0.04
-0.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$25.38
Aprire:
$25.41
Volume 24 ore:
36.95M
Relative Volume:
0.93
Capitalizzazione di mercato:
$146.35B
Reddito:
$63.83B
Utile/perdita netta:
$10.77B
Rapporto P/E:
13.69
EPS:
1.88
Flusso di cassa netto:
$12.44B
1 W Prestazione:
+2.51%
1M Prestazione:
+6.10%
6M Prestazione:
-2.13%
1 anno Prestazione:
-11.33%
Intervallo 1D:
$25.37
$25.89
Intervallo di 1 settimana:
$24.97
$25.89
Portata 52W:
$20.91
$30.43
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.74 | 142.54B | 63.83B | 10.77B | 12.44B | 1.88 |
|
LLY
Lilly Eli Co
|
709.82 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.93 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
209.50 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.82 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
86.08 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
How Much Would It Take To Earn $100 A Month From Pfizer Stock - Yahoo Finance
Pfizer Rises 0.24% Amid Legal and Clinical Setbacks, Trading Volume Ranks 92nd - AInvest
Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates - GlobeNewswire Inc.
Enanta files patent suit against Pfizer in Europe - Endpoints News
Pfizer battles another Paxlovid lawsuit from Enanta - Yahoo Finance
Myositis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Roche, Pfizer, Zydus Group, Lupin, Bausch Health, Accord Healthcare, Genentech - Barchart.com
Pfizer’s Latest Study on NSCLC Treatment: A Potential Game-Changer? - TipRanks
Pfizer sued by Enanta in EU patent fight (ENTA:NASDAQ) - Seeking Alpha
Enanta Pharmaceuticals Sues Pfizer Over Patent Infringement - TipRanks
Enanta files patent infringement suit against Pfizer over Paxlovid - Investing.com
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union - FinancialContent
Stock Analysis | Pfizer OutlookMixed Signals Amid Volatile Market Dynamics - AInvest
How Pfizer Inc. (PFE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Why Pfizer’s (PFE) Oncology Gamble is Finally Paying Off - TipRanks
Pfizer says Canada just approved its new COVID-19 vaccine for this fall - Global News
Pfizer, Astellas Beat Challenge To Prostate Cancer Drug Patent - Law360
Pfizer Oncology Drugs Drive Sales In Q2: Will The Trend Continue? - Barchart.com
Pfizer Inc. Stock (PFE) Opinions on Recent Clinical Trial Results - Quiver Quantitative
Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue? - Yahoo Finance
Pfizer Canada and HPIC Mark 30 Years of Humanitarian Partnership Delivering Global Health Impact - Seeking Alpha
Analyst recommendations: Arista Networks, Caterpillar, Pfizer, Broadcom, Nvidia… - MarketScreener
Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True? - Yahoo Finance
Pfizer Canada and BioNTech Receive Health Canada Approval of LP.8.1 Variant Adapted COVID-19 Vaccine - BioSpace
Lobbying Update: $3,710,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Pfizer/BioNTech updated COVID vaccine authorized in Canada - Seeking Alpha
Third Sickle Cell Product From Pfizer’s Global Blood Buyout Hits Snag - insights.citeline.com
Hung Trinh: Pfizer Completes Licensing Agreement with 3SBio - Oncodaily
Pfizer price surrounded with positive pressuresForecast today18-08-2025 - Economies.com
Pfizer’s sickle cell disease candidate fails Phase III trial - Yahoo Finance
Pfizer sickle cell hopes dim as inclacumab fails in late-stage trial - The Pharma Letter
Pfizer suffers another hit to its GBT sickle cell portfolio - pharmaphorum
Arvinas, Pfizer’s Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment - Yahoo Finance
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
Pfizer's Value Re-rating: Can Strong Institutional Interest and a Revitalized R&D Pipeline Justify a Buy? - AInvest
Citi Raises PT on Pfizer Inc. (PFE) to $26; Maintains ‘Neutral’ Rating - MSN
Pfizer Inc. - Britannica
Padcev plus Keytruda significantly improves survival for certain patients with bladder cancer when given... - Medical Dialogues
Pfizer's Sickle Cell Drug Fails to Meet Main Goal, Safety Profile Remains a Potential Asset - AInvest
Can Pfizer Inc. maintain its current growth rateJuly 2025 Macro Moves & Intraday High Probability Setup Alerts - thegnnews.com
Is Pfizer's Turnaround Real, and Is the 6.5% Dividend Safe? - AInvest
Pfizer: This Is What Bulls Waited For - Seeking Alpha
Pfizer Reports Positive Topline Phase 3 Results For HYMPAVZI™ In Hemophilia A or B With Inhibitors - MSN
Pfizer’s Phase 3 Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis Treatment - MSN
Pfizer and AbbVie Advance Pediatric Antibiotic Study: Market Implications - MSN
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings - MSN
Pfizer’s Pediatric Migraine Study: A Potential Game-Changer? - MSN
Pfizer’s Tukysa Study: A Closer Look at Its Korean Market Impact - MSN
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Pfizer’s Talzenna®: New Korea PMS Study Update and Market Insights - TipRanks
Pfizer’s Promising Migraine Study: A New Hope for Adolescents - TipRanks
A US FDA Move to Revoke Pfizer’s Pediatric COVID-19 Vaccine EUA Could Raise Supply Questions - insights.citeline.com
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.18%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):